IBM reports first-quarter 2026 earnings Wednesday after the close, with a 5 p.m. ET conference call and a Street consensus of $1.81 earnings per share on $15.60 billion in revenue. [1] The stock closed near $236 on Monday, off from a 52-week high closer to $325. [2] The paper's April 20 Wednesday preview sets the framing that matters: the $9.5 billion GenAI-and-watsonx book management disclosed last quarter now meets its first full peace-priced-market test.

The test is disaggregation. IBM's GenAI book is the company's single largest narrative asset; the Q4 disclosure rolled software, consulting, and infrastructure committed to GenAI engagements into one number. Wednesday's prepared remarks will either break that number out by segment — telling investors what is product revenue, what is consulting engagement, what is channel — or leave the $9.5 billion as a single line. The April 1 Arm strategic collaboration and the April 1 FedRAMP authorization of 11 watsonx solutions are the most recent data points in the enterprise story IBM is telling. [3]

Against a tape where Anthropic's rate-limit week, Moonshot's Kimi K2.6 Monday open-source release, and Cerebras's refiled S-1 have compressed the AI-revenue credibility window, the IBM call is the first blue-chip earnings test of whether GenAI bookings translate to margins. If the $9.5 billion holds as a product-and-services split with disclosed attach rates, the watsonx book is a business. If it is restated or smoothed, Wednesday is the day the market prices the difference.

-- THEO KAPLAN, San Francisco